These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 23811319)

  • 1. Depletion of regulatory T cells by targeting folate receptor 4 enhances the potency of a GM-CSF-secreting tumor cell immunotherapy.
    Liang SC; Moskalenko M; Van Roey M; Jooss K
    Clin Immunol; 2013 Aug; 148(2):287-98. PubMed ID: 23811319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
    Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
    Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of the anti-tumor efficacy of a GM-CSF-secreting tumor cell immunotherapy in preclinical models by cytosine arabinoside.
    Lin JM; Li B; Rimmer E; VanRoey M; Jooss K
    Exp Hematol; 2008 Mar; 36(3):319-28. PubMed ID: 18279719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy.
    Li B; VanRoey MJ; Jooss K
    Clin Immunol; 2007 May; 123(2):155-65. PubMed ID: 17320482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
    Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
    Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
    Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
    Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.
    Li B; Lin J; Vanroey M; Jure-Kunkel M; Jooss K
    Clin Immunol; 2007 Oct; 125(1):76-87. PubMed ID: 17706463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPARγ Contributes to Immunity Induced by Cancer Cell Vaccines That Secrete GM-CSF.
    Goyal G; Wong K; Nirschl CJ; Souders N; Neuberg D; Anandasabapathy N; Dranoff G
    Cancer Immunol Res; 2018 Jun; 6(6):723-732. PubMed ID: 29669721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration of IFN-alpha enhances the efficacy of a granulocyte macrophage colony stimulating factor-secreting tumor cell vaccine.
    Prell RA; Li B; Lin JM; VanRoey M; Jooss K
    Cancer Res; 2005 Mar; 65(6):2449-56. PubMed ID: 15781661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.
    Quezada SA; Peggs KS; Curran MA; Allison JP
    J Clin Invest; 2006 Jul; 116(7):1935-45. PubMed ID: 16778987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines.
    Jinushi M; Hodi FS; Dranoff G
    Immunol Rev; 2008 Apr; 222():287-98. PubMed ID: 18364009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting.
    Lipson EJ; Sharfman WH; Chen S; McMiller TL; Pritchard TS; Salas JT; Sartorius-Mergenthaler S; Freed I; Ravi S; Wang H; Luber B; Sproul JD; Taube JM; Pardoll DM; Topalian SL
    J Transl Med; 2015 Jul; 13():214. PubMed ID: 26143264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.
    Ko K; Yamazaki S; Nakamura K; Nishioka T; Hirota K; Yamaguchi T; Shimizu J; Nomura T; Chiba T; Sakaguchi S
    J Exp Med; 2005 Oct; 202(7):885-91. PubMed ID: 16186187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TGF-β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner.
    Soares KC; Rucki AA; Kim V; Foley K; Solt S; Wolfgang CL; Jaffee EM; Zheng L
    Oncotarget; 2015 Dec; 6(40):43005-15. PubMed ID: 26515728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
    Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
    J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma.
    Chu Y; Wang LX; Yang G; Ross HJ; Urba WJ; Prell R; Jooss K; Xiong S; Hu HM
    J Immunother; 2006; 29(4):367-80. PubMed ID: 16799332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing therapy of B16F10 melanoma efficacy through tumor vaccine expressing GPI-anchored IL-21 and secreting GM-CSF in mouse model.
    Zhao F; Dou J; He XF; Wang J; Chu L; Hu W; Yu F; Hu K; Wu Y; Gu N
    Vaccine; 2010 Apr; 28(16):2846-52. PubMed ID: 20153795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion.
    Teng MW; Swann JB; von Scheidt B; Sharkey J; Zerafa N; McLaughlin N; Yamaguchi T; Sakaguchi S; Darcy PK; Smyth MJ
    Cancer Res; 2010 Apr; 70(7):2665-74. PubMed ID: 20332236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The anti-tumor activity of GM-CSF-modified lung cancer cell vaccine and its synergism in combination with chemotherapy].
    Jiang HJ; Ren XB; Li H; Yu JP; Wei F; Ma MQ
    Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):808-12. PubMed ID: 18396635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.